BioSpace News Archive

ImmaticsN.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, reported its financial results for the quarter ended June 30, 2021 and provided a business update on its progress over the reporting period.

Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced financial results for the second quarter ended June 30, 2021, and highlighted recent corporate accomplishments.

Clene Inc today reported its second quarter 2021 operating and financial results.

Finch Therapeutics Group, Inc. today reported financial results for the second quarter ended June 30, 2021 and provided a business update.

Fulcrum Therapeutics, Inc. today provided a business update and reported financial results for the second quarter of 2021.

Fulcrum Therapeutics, Inc. today announced positive interim results from the ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy adult volunteers.

Recro Pharma, Inc. announced that it has signed a non-binding letter of intent for its acquisition of a full service CDMO with capabilities that range from formulation development to commercial manufacturing for various dosage forms including oral liquids, sterile injectables, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles.

BioXcel Therapeutics, Inc. today announced its financial results for the second quarter ended June 30, 2021 and provided an update on key strategic initiatives.

The regenerative medicine company Seraxis today announces that Shelley Hartman , Jerry Baty , and Min-Jung Choi are appointed to its Board of Directors.

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced results for the second quarter ended June 30, 2021 and provided a business update.